US FDA launches AI tool to reduce time taken for scientific reviews
(Reuters) -The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews.
"Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers," said FDA Commissioner Marty Makary.
The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets.
Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision.
Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts.
"Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff," the FDA said.
In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
FDA Inspection Preparedness and Compliance Course Webinar: Fundamentals and the Ground Rules on How to Prepare for and Survive an FDA Inspection
DUBLIN--(BUSINESS WIRE)--Jun 4, 2025-- The 'FDA Inspection Preparedness and Compliance' training has been added to offering. This is a practical, hands-on two-day seminar designed to provide pharmaceutical, biopharmaceutical, biologics and medical device professionals with the information and tools they require to prepare for and manage an FDA inspection efficiently, effectively and successfully. Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. The course will go through what typically goes on during an FDA Inspection and will then cover how to prepare for, host and follow up to a regulatory inspection. It will emphasize and focus on the critical and vital elements that you should do or not do during the inspection. Typically, FDA inspections can be highly structured and there are procedures that are to be followed as you prepare for state of readiness. It is important for anyone who might be involved in the inspection to be aware of these procedures, including all employees and personnel to ensure there are no surprises. The course will also provide information for inspections conducted by international agencies as well as non- FDA agencies, including self-inspections for manufacturing and the famous FDA Mock Inspection or Mock Audit. It will explain how to prepare for an inspection, how to handle a scheduled or non-scheduled inspection, what to expect during an inspection and what follow up to expect after an inspection. Who Should Attend: This seminar will provide an overview and in-depth snapshot of the entire process for preparing for and managing and FDA inspection and external regulatory inspections and for those companies who must establish proven and sustainable GXP Compliance Strategies and risk mitigation strategies when responding to a crisis. Employees who will benefit include all levels of management and departmental representatives from key functional areas and those who desire a better understanding or a 'refresh' overview of the FDA inspection process from preparing for the inspections, during the inspections and post-inspection responsibilities and follow up activities with FDA, including: This training Seminar includes the following for each registered attendee: Key Topics Covered: Day 1 Day 2 Recap of Day 1 and Day 2 Exercise on Day 2 Debrief/Adjourn/Wrap-Up Speakers: Kelly Thomas Vice President Stallergenes Greer Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation. Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MEDICAL DEVICES SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/04/2025 09:47 AM/DISC: 06/04/2025 09:45 AM
Yahoo
21 minutes ago
- Yahoo
Trump defeats Democrats' lawsuit over election commission independence
By Jonathan Stempel (Reuters) -A Washington, D.C. judge has dismissed the Democratic Party's lawsuit accusing U.S. President Donald Trump of violating federal election law by trying to assert control over the independent Federal Election Commission. U.S. District Judge Amir Ali ruled on Tuesday night that three national Democratic committees lacked a "concrete and imminent injury" to justify suing now, because they did not show Trump would violate election law. The lawsuit filed on February 28 was the Democratic Party's first against Trump during the Republican's second White House term. Hundreds of lawsuits challenging the administration's actions have been filed. Neither the Democratic party nor its lawyers immediately responded to requests for comment on Wednesday. The White House did not immediately respond to a similar request. Democrats challenged Trump's February 18 executive order giving the White House more control over traditionally independent agencies including the election commission, National Labor Relations Board and Securities and Exchange Commission. They objected to language making Trump's and Attorney General Pam Bondi's views on questions of law "controlling" for federal employees performing their official duties, and bans executive branch employees from advancing contrary views. The plaintiffs included the Democratic National Committee, Democratic Senatorial Campaign Committee and Democratic Congressional Campaign Committee. In a 14-page decision, Ali said White House lawyers assured that the administration would not invoke Trump's order to dictate election commission activity, and commissioners would not interpret the order as a command to vote a particular way. Ali, an appointee of Democratic President Joe Biden, also found no imminent injury based on Democrats' claim they were "chilled" from pursuing campaign strategies because a Trump-controlled election commission might reject them. "The court does not doubt that the committees would have cause for profound concern were the FEC's independence to be compromised," the judge wrote. But he said Supreme Court precedent required the committees to show that their relationship with the bipartisan commission has changed or will change. "They have not done so," he said. The election commission oversees elections and enforces campaign finance laws. Congress created it in 1974 in the wake of the Watergate scandal. The case is Democratic National Committee et al v Trump et al, U.S. District Court, District of Columbia, No. 25-00587.
Yahoo
21 minutes ago
- Yahoo
US private payrolls post smallest gain in over two years in May
WASHINGTON (Reuters) - U.S. private employers added the fewest number of workers in more than two years in May, but the data is probably not a true reflection of the labor market, which is gradually easing amid economic uncertainty over the Trump administration's tariffs. Private payrolls increased by only 37,000 jobs last month, the smallest gain since March 2023, after a downwardly revised rise of 60,000 in April, the ADP National Employment Report showed on Wednesday. Economists polled by Reuters had forecast private employment would advance by 110,000 following a previously reported increase of 62,000 in April. The ADP report, jointly developed with the Stanford Digital Economy Lab, was published ahead of the more comprehensive employment report for May that is due to be released on Friday by the Labor Department's Bureau of Labor Statistics. There is no correlation between the ADP and BLS employment reports. Government data on Tuesday showed there were 1.03 job openings for every unemployed person in April, little changed from March. "As usual, we suggest ignoring the message from the ADP employment report, mostly because it has had a very poor track record in recent years," said Oliver Allen, senior U.S. economist at Pantheon Macroeconomics. The services sector accounted for nearly all the new jobs last month, with payrolls in that category rising by 36,000. That reflected gains in the financial activities, information as well as leisure and hospitality industries. Goods producing sector payrolls declined by 2,000, pulled down by job losses in the manufacturing and mining industries. "Use ADP only to gauge the big picture," said Carl Weinberg, chief economist at High Frequency Economics. "Right now, that picture shows ADP's private sector employment estimates declining steadily since December." The BLS is expected to report that private payrolls increased by 120,000 jobs in May after advancing by 167,000 in April, a Reuters survey showed. Overall nonfarm payrolls are estimated to have increased by 130,000 jobs after rising by 177,000 in April. The unemployment rate is forecast to be unchanged at 4.2%.
